secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2023-08-29T23:59:59+00:00
Accession:  0000950170-23-045111
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen Phase 3 pamrevlumab trial for DMD fails to meet primary endpoint
-------------------------------------------------------------------------

- Primary endpoint (NSAA total score change at week 52) not met: mean difference -0.528 points (p=0.5553).
- All secondary endpoints including stair climb velocity and 10-meter walk/run test also not met.
- Pamrevlumab was generally safe and well tolerated; SAEs 8.3% pamrevlumab vs 2.8% placebo.
- Company evaluating total data and will share full results at a future medical forum.
- Interim CEO Thane Wettig expressed disappointment and gratitude to trial participants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017023045111/0000950170-23-045111-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017023045111/fgen-20230829.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-045111

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer